MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?

MDMA-assisted psychotherapy shows exceptional efficacy for PTSD and medication-resistant depression, with 40-60% of people with PTSD not responding to standard antidepressants. The FDA designated it a breakthrough therapy in 2017, Phase 3 trials are underway, and expanded access was granted in the US and Israel in 2020. Approval could come as early as 2024, offering a potential treatment for a condition affecting almost 3.5% of US adults.

Study at a glance

Abstract

In recent years, scientists have initiated a renaissance in psychedelic research following decades of prohibition. Compounds such as ketamine, LSD, and psilocybin 'once primarily associated with recreational use' are now being investigated for their therapeutic potential, with promising results. An estimated 40-60% of people with post-traumatic stress disorder (PTSD) do not respond to selective serotonin reuptake inhibitors, which are the first-line medications for this condition. However, one standout among these psychedelics is methylenedioxy methamphetamine (MDMA), which has demonstrated exceptional efficacy in treating PTSD and medication-resistant depression. Growing results in research were so positive that, in 2017, the US Food and Drug Administration (FDA) designated MDMA-assisted psychotherapy as a breakthrough therapy. Though MDMA is not yet officially legal or approved for clinical use, Phase 3 trials are underway, and expanded access status was granted in 2020 in the United States and Israel. Preliminary clinical studies are extremely promising, and the FDA could approve MDMA-assisted psychotherapy for PTSD as early as 2024, offering a potential treatment for this crippling mental health condition that affects almost 3.5% of US adults.